# Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC

> **NCT07750704** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Guangdong Association of Clinical Trials** · enrollment: 153 (estimated)

## Conditions studied

- ALK Positive Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Lorlatinib
- **DRUG:** sacituzumab tirumotecan plus lorlatinib

## Key facts

- **NCT ID:** NCT07750704
- **Lead sponsor:** Guangdong Association of Clinical Trials
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2029-09
- **Final completion:** 2030-03
- **Target enrollment:** 153 (ESTIMATED)
- **Last updated:** 2026-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07750704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07750704, "Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07750704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*